Legend Biotech Single Domain Antibodies CAR-T BCMA
Summary
EPO published patent application EP4077398A1 covering single domain antibodies and chimeric antigen receptors targeting BCMA, assigned to Legend Biotech Ireland Limited and Legend Biotech USA Inc. The invention relates to cancer treatment methods using BCMA-targeted CAR-T cells and single domain antibodies. Six inventors are listed: Fan Xiaohu, Zhuang Qiuchuan, Zhao Yuncheng, Yang Lei, Fang Xu, and Xu Changmeng.
“SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF”
About this source
GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
EPO granted patent EP4077398A1 to Legend Biotech covering single domain antibodies and chimeric antigen receptors targeting BCMA (B-cell maturation antigen) for cancer treatment applications. The patent designates all EPC contracting states including Germany, France, UK, Italy, Spain, Netherlands, Sweden, Belgium, Austria, and 21 other European states.
Pharmaceutical and biotechnology companies developing CAR-T therapies or BCMA-targeted biologics should review this patent for freedom-to-operate implications in European markets. The wide geographic designation means the IP rights extend across most major European pharmaceutical markets.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
Publication EP4077398A1 Kind: A1 Apr 15, 2026
Applicants
Legend Biotech Ireland Limited, Legend Biotech USA Inc.
Inventors
FAN, Xiaohu, ZHUANG, Qiuchuan, ZHAO, Yuncheng, YANG, Lei, FANG, Xu, XU, Changmeng
IPC Classifications
C07K 19/00 20060101AFI20240305BHEP C07K 14/725 20060101ALI20240305BHEP C07K 16/28 20060101ALI20240305BHEP C12N 5/0783 20100101ALI20240305BHEP C12N 5/10 20060101ALI20240305BHEP A61K 39/395 20060101ALI20240305BHEP A61P 35/00 20060101ALI20240305BHEP A61P 35/02 20060101ALI20240305BHEP A61K 39/00 20060101ALI20240305BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.